176 related articles for article (PubMed ID: 37173881)
1.
Zimpfer A; Kdimati S; Mosig M; Rudolf H; Zettl H; Erbersdobler A; Hakenberg OW; Maruschke M; Schneider B
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173881
[TBL] [Abstract][Full Text] [Related]
2. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
[TBL] [Abstract][Full Text] [Related]
3. ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy.
McAfee JL; Hoda RS; Hoyle C; McCoy L; Sprague C; Reddy CA; Koyfman SA; Geiger JL; Komforti MK; Griffith CC
Mod Pathol; 2023 Oct; 36(10):100273. PubMed ID: 37423585
[TBL] [Abstract][Full Text] [Related]
4. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.
Schneider SA; Sukov WR; Frank I; Boorjian SA; Costello BA; Tarrell RF; Thapa P; Houston Thompson R; Tollefson MK; Jeffrey Karnes R; Cheville JC
Mod Pathol; 2014 May; 27(5):758-64. PubMed ID: 24186136
[TBL] [Abstract][Full Text] [Related]
5. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
6. Human epidermal growth factor receptor 2 (
Agrawal V; Bharti N; Pandey R
Arab J Urol; 2020 Sep; 18(4):267-272. PubMed ID: 33312739
[TBL] [Abstract][Full Text] [Related]
7. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
Ni R; Mulligan AM; Have C; O'Malley FP
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis.
Rizzo A; Mollica V; Santoni M; Massari F
Clin Genitourin Cancer; 2022 Oct; 20(5):482-487. PubMed ID: 35858936
[TBL] [Abstract][Full Text] [Related]
9. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
Mentrikoski MJ; Stoler MH
Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
[TBL] [Abstract][Full Text] [Related]
10. High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines.
Vergara-Lluri ME; Moatamed NA; Hong E; Apple SK
Mod Pathol; 2012 Oct; 25(10):1326-32. PubMed ID: 22699517
[TBL] [Abstract][Full Text] [Related]
11. HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients.
Sasaki Y; Sasaki T; Kawai T; Morikawa T; Matsusaka K; Kunita A; Kume H; Aoki I; Homma Y; Fukayama M
Int J Clin Exp Pathol; 2014; 7(2):699-708. PubMed ID: 24551292
[TBL] [Abstract][Full Text] [Related]
12. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
[TBL] [Abstract][Full Text] [Related]
13. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma.
Kim G; Chung YR; Kim B; Song B; Moon KC
J Pathol Transl Med; 2016 Nov; 50(6):436-441. PubMed ID: 27725621
[TBL] [Abstract][Full Text] [Related]
15. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.
Lassus H; Leminen A; Vayrynen A; Cheng G; Gustafsson JA; Isola J; Butzow R
Gynecol Oncol; 2004 Jan; 92(1):31-9. PubMed ID: 14751135
[TBL] [Abstract][Full Text] [Related]
16. Reappraisal of HER2 Amplification in High-Grade Urothelial Carcinoma Based on 2018 ASCO/CAP Clinical Practice Guidelines.
Mohanty SK; Mishra SK; Tiwari A; Sharma S; Bhardwaj M; Pattnaik N; Jaiswal S; Baisakh MR; Das S; Pradhan MR; Swain TR; Satpathy K; Williamson SR; Parwani AV
Am J Clin Pathol; 2021 Nov; 156(6):1130-1141. PubMed ID: 34124742
[TBL] [Abstract][Full Text] [Related]
17. HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.
Aumayr K; Klatte T; Neudert B; Birner P; Shariat S; Schmidinger M; Susani M; Haitel A
Pathol Oncol Res; 2018 Jul; 24(3):575-581. PubMed ID: 28755093
[TBL] [Abstract][Full Text] [Related]
18. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
[TBL] [Abstract][Full Text] [Related]
19. Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis.
Sevillano E; Werner L; Bossé D; Lalani AA; Wankowicz SAM; de Velasco G; Farina M; Lundgren K; Choueiri TK; González Del Alba A; Bellmunt J
Clin Genitourin Cancer; 2017 Dec; 15(6):e1089-e1094. PubMed ID: 28864222
[TBL] [Abstract][Full Text] [Related]
20. HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts.
Eriksson P; Sjödahl G; Chebil G; Liedberg F; Höglund M
Oncotarget; 2017 Jul; 8(30):48905-48914. PubMed ID: 28388586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
